Thursday, 28 May 2020

Cipla launches Daptomycin for Injection

26 September 2019 | News

Daptomycin for Injection, 500mg/vial, single-dose vial for intravenous use only

image credit-

image credit-

Cipla Limited and its subsidiary Cipla USA, Inc., (hereafter referred to as “Cipla”), The pharmaceuticals and drug company, announce the launch of Daptomycin for Injection, 500mg/vial, single-dose vial, AP-rated generic equivalent of Cubicin® for Injection in the United States. 

According to IQVIA (IMS Health), Cubicin® for Injection (daptomycin for injection) had U.S. sales of approximately $606 Million for the 12-month period ending June 2019. The product is available for shipping immediately.


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account